Table 1.
Sample and clinical study overview.
| Ct.gov identifier, Study ID and other reference | Phase and patient population | Study drug(s) | Total number of samples (number of patients receiving CPI combination treatment) | |
|---|---|---|---|---|
| Screening | On treatment | |||
|
NCT02304393, BP29392 Barlesi et al., 2020 |
Phase Ib, advanced solid tumors | Selicrelumab (anti-PD-L1; RO7009789) in combination with atezolizumab | 39 (37) | 32 (31) |
| NCT02350673, BP29435, Van Brummelen et al., 2018 | Phase Ib, locally advanced and/or metastatic carcinoembryonic antigen (CEA)-positive solid tumors | Cergutuzumab amunaleukin (CEA-IL2v, RO6895882) in combination with atezolizumab | 12 (12) | 5 (5) |
| NCT02627274, BP29842, Melero et al., 2018 | Phase Ia/Ib, metastatic solid tumors | Simlukafusp alfa (FAP IL2v, RO6874281) as a single agent or in combination with trastuzumab or cetuximab | 24 (0) | 12 (0) |
| NCT02665416, BP29889 | Phase Ib, metastatic solid tumors | Selicrelumab (RO7009789) with vanucizumab or bevacizumab | 28 (0) | 15 (0) |
| NCT03063762, BP39365 | Phase Ib, unresectable advanced and/or metastatic renal cell carcinoma (RCC) | Simlukafusp alfa (FAP IL2v, RO6874281) in combination with atezolizumab with/without bevacizumab | 20 (18) | 16 (15) |
| NCT03386721, BP40234, Italiano et al., 2021 | Phase II, advanced and/or metastatic solid tumors | Simlukafusp alfa (FAP IL2v, RO6874281) in combination with atezolizumab | 63 (60) | 37 (37) |
| NCT03875079, BP41054 | Phase Ib, advanced or metastatic melanoma | Simlukafusp alfa (FAP IL2v, RO6874281) in combination with pembrolizumab | 26 (26) | 0 |
This table lists the metastatic biopsy samples derived from Phase I Roche clinical trials which were used in this study, the associated Roche-sponsored clinical trials and treatments investigated, and the respective number of patients receiving combination treatment with CPI (either Atezolizumab or Pembrolizumab).